How ranibizumab became a major treatment for people with wet AMD

摘要

IN LESS than a decade, the vascular endothelial growth factor (VEGF) inhibitor ranibizumab (Lucentis) has not only transformed the prognosis for the 26,000 people diagnosed with wet age-related macular degeneration (AMD) each year, it has helped to reshape clinical thinking about neovascular eye disease.